Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545487 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4909693 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3883464 | 0.91 | TSHR (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL13839552 | 0.91 | TSHR (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453899 | 0.88 | TSHR (0.61) | CA1CA2CA7CA9TSHR | |
| SCHEMBL1195445 | 0.85 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL12361734 | 0.83 | AGXT (0.44) | CA1CA2CA7CA9KMT2A | |
| SCHEMBL12519871 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR | |
| SCHEMBL10052366 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR | |
| SCHEMBL13003073 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254539-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-4172958-A | Ethers of 2,6,10-trimethyl-undecan-1-ols | HOFFMANN-LA ROCHE INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4169209-A | Ethers of 2,6-dimethyl-octane-1,8-diols | HOFFMANN-LA ROCHE INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4163021-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4151205-A | Synthesis of vitamin E | HOFFMAN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4140723-A | Intermediate compounds for producing vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4140702-A | Process for producing vitamin E intermediate compounds | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4111961-A | Silicon ester of carboxylic acid | HOFFMANN-LA ROCHE INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4107183-A | Synthesis of optically active carboxylic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4051153-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4041058-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099694-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | SUZ12, BRPF3, BRD4 | CA1 4395/4885CA2 4554/4885CA7 4668/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | CA1 4140/4885CA2 1930/4885CA7 1096/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CA1 4863/4885CA2 4252/4885CA7 4721/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | CA1 963/4885CA2 1321/4885CA7 1117/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CA1 4863/4885CA2 4252/4885CA7 4721/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | CA1 4779/4885CA2 4793/4885CA7 2431/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | CA1 4863/4885CA2 4252/4885CA7 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.